Bachelor of Peking University, Ph.D. from the University of Pennsylvania, Postdoctoral Fellow at the University of Wisconsin-Madison

One of the international pioneers of hiPSC technology: In 2007, together with Professor James Thomson, the "Father of Human Embryonic Stem Cells", as the first and corresponding author, she reported in Science the successful conversion of human skin cells into induced pluripotent stem cells (iPSCs) under in vitro culture conditions (simultaneously published with Professor Shinya Yamanaka's team in Cell). This achievement earned her selection as a TIME Magazine Person of the Year.

Pioneer of non-integrating reprogramming technology: In 2009, Dr. Junying Yu's groundbreaking work was published in Science, achieving the first generation of footprint-free human iPSCs without exogenous gene DNA damage.

Academic to industrial transformation: From 2009 to 2015, she served as Director of the Advanced R&D Department at Cellular Dynamics International, founded by Professor James Thomson, dedicated to translating stem cell technologies from research to production and developing related cell products.

Leading China's hiPSC industry development: In 2016, she founded Nuwacell Biotechnologies Co., Ltd. as Chief Scientist, focusing on developing widely accessible iPSC-derived cell therapy products.

Bachelor of the University of Science and Technology of China, Ph.D. and Postdoctoral Fellow of Cornell University

A leading expert in hiPSC industrialization: With years of domestic and international experience in the hiPSC industrial transformation, he joined Cellular Dynamics International as a Senior Scientist in the Advanced R&D Department, where he participated in establishing large-scale hiPSC preparation and directed differentiation processes.

National project leadership: Undertaken key projects under the 13th and 14th Five-Year National Key R&D Programs of MOST, including "Standardized Research on Stem Cell Preparations and Applications", "Quality Control and Evaluation Technology for Stem Cells and Related Products", and "Research on R&D and Regulatory Evaluation Technology for Stem Cells and Their Derivative Innovative Drugs".

Pipeline development leadership: Founded Nuwacell Biotechnologies Co., Ltd. in 2016 as Chief Technology Officer, completing the establishment and quality validation of multiple clinical-grade hiPSC tertiary banks. He has developed diverse hiPSC-derived cell drug pipelines (e.g., iMSC, iNK, iDAP, islet cells) and advanced multiple projects into registered clinical trial stages.

Ph.D., Sun Yat-sen University

Dr. Jiao is mainly responsible for the research and development of new drug pipeline projects, with profound medical expertise and experience in drug development, as well as excellent capabilities in strategic planning, project management and risk control.

Dongbei University of Finance & Economics

Xu is mainly responsible for public relations affairs, with more than 20 years of experience in public affairs management of large management companies. He has rich practical experience in the development and maintenance of government, industry associations, media and public relations, etc.

Central University of Finance and Economics, EDHEC Business School, DrPH Candate at Johns Hopkins University

Mr. Lin is responsible for spearheading the development and execution of the company’s financial strategies and driving business development initiatives. With over a decade of experience in asset management and investment banking across both international and Chinese markets, as well as more than 9 years in the pharmaceutical and biotech sectors, Mr. Lin has held senior roles including Board Secretary and SVP of Operations at several prominent domestic companies. He is recognized for his long-term strategic vision, sharp market analysis, strong negotiation skills, and robust expertise in risk management.

Gannan Medical University

Jiang is mainly responsible for overseeing and managing the overall operation of clinical trials. With over 100 projects managing experience and more than 16 years of team management experience, she demonstrates remarkable abilities in organization, coordination, communication, and strategic planning.

University of Science and Technology of China

Han is mainly responsible for human resources and administrative work. She has 10+ years of administrative management experience in listed companies. She is proficient in laws, regulations and best practices in human resources and administrative management, with excellent leadership, management and communication skills.

Anhui University of Chinese Medicine

Zheng is mainly responsible for a series of work related to the declaration and registration of new drug pipelines, proficient in domestic and foreign drug management and registration policies, regulations and guiding principles. She has rich experience in project operation, drug information analysis and research, declaration and registration, communication with regulatory authorities, etc.

Shenyang Pharmaceutical University

Hui Ma is responsible for the quality assurance and compliance management throughout the entire aseptic production process. She has over 20 years of experience in the pharmaceutical industry, including more than 10 years with multinational companies. She has held key positions at well-known pharmaceutical companies such as GlaxoSmithKline (GSK), Novozymes, and Asymchem. Ms. Ma is highly knowledgeable in international regulatory standards such as GMP, FDA, and ICH. She has participated in multiple regulatory inspections conducted by authorities including the NMPA and MHRA, and brings extensive expertise in quality management, risk control, and team leadership.

Nanjing University

Liu is mainly responsible for the customization of pharmacological and toxicological strategies and the development of trials of new drug pipelines, and has deep knowledge of pharmacology and toxicology and rich experience in drug research and development.

Fudan University

Li is mainly responsible for the company's medical affairs related work. She has more than 14 years of experience in medical and clinical research and drug development in the treatment fields of rare diseases, immunity and tumors. She has held important positions in many multinational pharmaceutical companies such as Eli Lilly, Novartis and Wyeth, where she was responsible for and managed multiple Phase I-II and Phase IV post-marketing studies.

Shanghai University of Traditional Chinese Medicine

Wang is mainly responsible for the planning, operation and management of clinical trial projects. She has been deeply involved in the cell therapy industry for several years with profound clinical trial experience and efficient communication and coordination skills.

Anhui University of Finance and Economics

Sun is mainly responsible for a series of tasks such as financial management, decision-making and supervision. She has many years of experience in financial management and analysis of listed companies, rich knowledge related to financial strategic management, keen market insight and risk control capabilities.

Ph.D., TechnicalInstitute of Physics and Chemistry CAS

Dr. Wang is mainly responsible for the formulation, implementation and management of intellectual property strategies. He has many years of experience in the establishment and operation of intellectual property management systems for listed companies. He is proficient in domestic and foreign intellectual property laws and policies, and has extensive intellectual property professional knowledge and skills.

Bengbu Medical College

Dong is mainly responsible for the establishment, implementation and optimization of quality management systems. He has many years of experience in building GMP quality management systems and team management for listed companies, and is proficient in laws and regulations related to quality management.